Business Description
Ovid Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US6904691010
Total Employee Number:
23Description
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.9 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.28 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 9.36 | |||||
Beneish M-Score | 8.64 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 67.1 | |||||
3-Year EBITDA Growth Rate | 9.4 | |||||
3-Year EPS without NRI Growth Rate | 33.2 | |||||
3-Year FCF Growth Rate | 13.5 | |||||
3-Year Book Growth Rate | -18.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -30.67 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -64.37 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 70.87 | |||||
9-Day RSI | 64.11 | |||||
14-Day RSI | 59.09 | |||||
3-1 Month Momentum % | 9.09 | |||||
6-1 Month Momentum % | 36.36 | |||||
12-1 Month Momentum % | 626.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.17 | |||||
Quick Ratio | 10.17 | |||||
Cash Ratio | 9.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.7 | |||||
Shareholder Yield % | -12.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -670.25 | |||||
Net Margin % | -339.33 | |||||
EBITDA Margin % | -667.9 | |||||
FCF Margin % | -589.06 | |||||
OCF Margin % | -589.06 | |||||
ROE % | -24.73 | |||||
ROA % | -20.16 | |||||
ROIC % | -93 | |||||
3-Year ROIIC % | 24.47 | |||||
ROC (Joel Greenblatt) % | -391.8 | |||||
ROCE % | -43.36 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 27.17 | |||||
PB Ratio | 2.27 | |||||
Price-to-Tangible-Book | 2.26 | |||||
EV-to-EBIT | -7.53 | |||||
EV-to-Forward-EBIT | -4.61 | |||||
EV-to-EBITDA | -7.56 | |||||
EV-to-Revenue | 50.49 | |||||
EV-to-Forward-Revenue | 705.99 | |||||
EV-to-FCF | -8.57 | |||||
Price-to-GF-Value | 0.32 | |||||
| Price-to-Net-Current-Asset-Value | 3.41 | |||||
| Price-to-Net-Cash | 3.49 | |||||
Earnings Yield (Greenblatt) % | -13.28 | |||||
FCF Yield % | -8.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OVID
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ovid Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.122 | ||
| EPS (TTM) ($) | -0.29 | ||
| Beta | 0.049 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 0.84 | ||
| Volatility % | 157.26 | ||
| 14-Day RSI | 59.09 | ||
| 14-Day ATR ($) | 0.176217 | ||
| 20-Day SMA ($) | 2.4285 | ||
| 12-1 Month Momentum % | 626.17 | ||
| 52-Week Range ($) | 0.326 - 3.105 | ||
| Shares Outstanding (Mil) | 186.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ovid Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ovid Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 41 days | ||
| General meeting for 2026 | 2026-07-09 10:30 | In 7 days | ||
| H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference | 2026-06-15 | 2.30 (+4.55%) | ||
| Oppenheimer CNS & Neuro-Muscular Summit | 2026-06-10 15:45 | 2.42 (+1.26%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 2.79 (-0.36%) | ||
| KCC2 Deep Dive R&D Event | 2026-04-14 09:30 | 2.79 (+2.20%) | ||
| Business and Pipeline Update | 2026-03-18 08:30 | 2.01 (+3.08%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-18 08:30 | 2.01 (+3.08%) | ||
| Annual report for 2025 | 2026-03-18 | 2.01 (+3.08%) |
Show
Entries
Ovid Therapeutics Inc Frequently Asked Questions
What is Ovid Therapeutics Inc(OVID)'s stock price today?
The current price of OVID is $2.69. The 52 week high of OVID is $3.11 and 52 week low is $0.33.
When is next earnings date of Ovid Therapeutics Inc(OVID)?
The next earnings date of Ovid Therapeutics Inc(OVID) is 2026-08-13 Est..
Does Ovid Therapeutics Inc(OVID) pay dividends? If so, how much?
Ovid Therapeutics Inc(OVID) does not pay dividend.
Guru Commentaries on NAS:OVID
No articles.
Press Release
Articles on Ovid Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers